JNJ SEC Filings

Johnson & Johnson (JNJ) reported its 2025 fiscal year results, highlighting continued growth across its two primary segments: Innovative Medicine and MedTech. The company's overall sales increased by 6.0% to $94.2 billion, driven by strong volume growth, partially offset by pricing pressures and foreign currency impacts. The Innovative Medicine segment saw a 6.0% sales increase, propelled by strong performance in Oncology products like DARZALEX and ERLEADA, as well as new launches, though the segment experienced a significant decline in STELARA sales due to biosimilar competition. The MedTech segment also reported a 6.1% sales increase, driven by robust growth in Cardiovascular franchises, particularly from the Abiomed and Shockwave acquisitions, and steady performance in Surgery and Vision. However, the Orthopaedics business experienced modest growth, impacted by restructuring efforts and volume-based procurement in China. The company announced its intention to separate its Orthopaedics business, a move expected to be completed within 18-24 months, which may reshape its operational focus. Financially, Johnson & Johnson's earnings before taxes increased significantly, largely due to a favorable litigation outcome reversing a substantial portion of the talc reserve. The company also continues to manage its capital structure, with increased debt to fund strategic acquisitions like Intra-Cellular Therapies, Inc. (CAPLYTA), while also increasing its dividend for the 63rd consecutive year. Key risks remain, including ongoing litigation, increasing regulatory scrutiny, and the competitive landscape for key products.

Johnson & Johnson (JNJ) has filed an 8-K report on January 21, 2026, to announce its financial results for the fourth quarter and full year ended December 28, 2025. The filing primarily directs investors to a press release (Exhibit 99.1) and supplementary data (Exhibit 99.2) for detailed sales and earnings information. While the 8-K itself does not contain the specific figures, these attached exhibits are the primary source for understanding the company's performance during the reported periods, including key financial metrics and operational achievements.

Johnson & Johnson (JNJ) reported robust financial results for the fiscal third quarter ending September 27, 2025. Sales increased by 6.8% year-over-year to $24.0 billion, driven by strong performance in both the Innovative Medicine and MedTech segments. Net earnings saw a significant jump to $5.2 billion, translating to diluted earnings per share of $2.12, compared to $2.7 billion and $1.11 in the prior year's third quarter. This performance reflects broad-based growth across key therapeutic areas and product lines, alongside effective cost management. The company demonstrated strong operational execution, with a positive impact from currency fluctuations and strategic acquisitions contributing to top-line growth. The balance sheet remains solid, with total assets growing to $192.8 billion. The company's strategic focus on innovation and portfolio management is evident in the performance of its Innovative Medicine segment, which saw sales rise by 6.8% driven by strong oncology and neuroscience offerings, notably bolstered by the recent acquisition of CAPLYTA. The MedTech segment also performed well, with sales increasing by 6.8%, supported by growth in Cardiovascular and Vision franchises, including contributions from the Shockwave acquisition. Despite ongoing legal matters, particularly related to talc and opioids, the company's financial strength and operational efficiency continue to drive shareholder value.

Johnson & Johnson has filed an 8-K report highlighting key developments from its third quarter of 2025. The company announced its sales and earnings results for the quarter ended September 28, 2025, providing investors with updated financial performance data. This report also contains a significant strategic announcement regarding the company's intention to separate its Orthopaedics business. This separation could reshape JNJ's business portfolio and potentially unlock value for shareholders by allowing each segment to focus on its distinct growth opportunities.

Johnson & Johnson (JNJ) has announced a significant addition to its Board of Directors with the election of John Morikis, effective September 8, 2025. Mr. Morikis brings extensive leadership experience, having served as Executive Chairman, President, and CEO of The Sherwin-Williams Company from 2016 to 2024, with a career spanning nearly forty years at the company. His appointment is expected to enhance the Board's expertise, particularly given his significant tenure in executive roles. Mr. Morikis has been assigned to key committees, including the Audit Committee and the Compensation & Benefits Committee, indicating his immediate and strategic role within the company's governance. His compensation as a non-employee director will align with the standard practices outlined in JNJ's 2025 Proxy Statement.

Johnson & Johnson (JNJ) reported a strong second quarter for fiscal year 2025, demonstrating robust sales growth and improved profitability. Worldwide sales increased by 5.8% to $23.7 billion, driven by solid performance across both the Innovative Medicine and MedTech segments. The Innovative Medicine segment saw a notable 4.9% increase in sales, propelled by strong oncology product performance, particularly from CARVYKTI and DARZALEX, alongside the recent acquisition of Intra-Cellular Therapies contributing to the neuroscience portfolio. The MedTech segment also delivered a healthy 7.3% sales increase, benefiting from the integration of Shockwave Medical and continued strength in cardiovascular and surgical solutions. Net earnings significantly rose to $5.5 billion, or $2.29 per diluted share, compared to $4.7 billion, or $1.93 per diluted share, in the prior year's quarter. This increase was significantly aided by the reversal of a substantial portion of the previously accrued talc reserve, which contributed positively to the 'Other (income) expense, net' line item. The company maintained its commitment to shareholders through dividend payments and share repurchases, underscoring a positive financial outlook.

Johnson & Johnson (JNJ) has filed an 8-K report detailing its second-quarter financial results for the period ended June 29, 2025. The filing primarily references a press release and supplementary financial data, providing investors with key operational and financial performance metrics for the recently concluded quarter. This report is crucial for understanding the company's recent sales trends and earnings, which are vital indicators of its ongoing business health and strategic execution within its diverse segments, including pharmaceuticals, medical devices, and consumer health. Investors should review the attached exhibits for a comprehensive understanding of the company's performance against expectations and its trajectory for the remainder of the fiscal year. The provided documentation includes the press release announcing Q2 2025 results and unaudited comparative supplementary sales data along with condensed consolidated statements of earnings. These materials are essential for evaluating Johnson & Johnson's financial condition and operational results, allowing for comparisons to prior periods and potentially to industry benchmarks. The market will be closely watching these figures to assess the impact of various economic factors, competitive pressures, and the company's strategic initiatives on its bottom line and revenue generation.

Johnson & Johnson (JNJ) has announced a significant addition to its Board of Directors with the election of Daniel Pinto, effective July 1, 2025. Mr. Pinto, currently President of JPMorgan Chase and set to become Vice Chairman, brings extensive financial expertise to the board. His appointment to both the Audit Committee and the Compensation & Benefits Committee is noteworthy, suggesting a focus on financial oversight and executive compensation strategies. This appointment comes with the disclosure of a prior business relationship between JNJ and JPMorgan Chase, with JNJ paying approximately $39.2 million in fiscal year 2024 for various banking services. Investors should note that while Mr. Pinto's role at JPMorgan Chase involves services provided to JNJ, his director compensation will be in line with the Company's standard non-employee director compensation as outlined in its proxy statement. This move signals a potential strengthening of JNJ's governance and financial acumen.

Johnson & Johnson (JNJ) filed an 8-K on April 29, 2025, reporting on the company's 2025 Annual Meeting of Shareholders held on April 24, 2025. The report details the outcomes of various shareholder votes, including the election of all 11 director nominees and the advisory approval of executive compensation. Notably, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. The filing also announced the upcoming retirement of board member D. Adamczyk, effective May 31, 2025, due to his decision to join Goldman Sachs as a Partner. This departure is stated to be for personal reasons and not a result of any disagreement with the company's management.

Johnson & Johnson (JNJ) reported a strong first quarter for fiscal year 2025, with worldwide sales reaching $21.9 billion, a 2.4% increase year-over-year. This growth was driven by a robust operational increase of 4.2%, partially offset by a 1.8% negative currency impact. The Innovative Medicine segment showed resilience with a 2.3% sales increase, fueled by strong performance in Oncology, particularly with products like Darzalex and CARVYKTI, despite a significant 33.7% decline in Stelara sales due to biosimilar competition. The MedTech segment also grew by 2.5%, boosted by the recent acquisition of Shockwave Medical and continued strength in Cardiovascular and Vision product lines. The company reported a substantial increase in net earnings to $11.0 billion from $3.3 billion in the prior year's quarter. This significant jump was largely influenced by the reversal of approximately $7.0 billion related to the previously accrued talc reserve, which had a material positive impact on the 'Other (income) expense, net' line item. Excluding this one-time item, operational performance remains solid, demonstrating the company's ongoing ability to drive growth across its diverse portfolio.

Johnson & Johnson (JNJ) has filed a Form 8-K on April 15, 2025, reporting key financial updates and shareholder returns. The company announced its first-quarter 2025 sales and earnings results, details of which are available in an accompanying press release. This provides investors with crucial performance metrics for the period ending March 30, 2025, enabling an assessment of the company's operational strength and market position. Furthermore, JNJ's Board of Directors has approved a 4.8% increase in its quarterly dividend, raising it from $1.24 to $1.30 per share. This marks the 63rd consecutive year of dividend increases, underscoring the company's commitment to returning capital to shareholders and its financial stability. The annualized dividend now stands at $5.20 per share, reflecting sustained dividend growth.

Johnson & Johnson (JNJ) has filed an 8-K report on April 2, 2025, disclosing a significant development regarding its subsidiary Red River Talc LLC. The U.S. Bankruptcy Court for the Southern District of Texas has denied the confirmation of Red River Talc LLC's proposed prepackaged bankruptcy plan. This decision carries substantial financial implications for the company.

Johnson & Johnson (JNJ) has announced the completion of a significant public offering of senior unsecured notes denominated in Euros. This offering, which closed on February 25, 2025, involved five tranches with varying maturities and coupon rates, totaling €4.0 billion. The notes were issued under the company's existing shelf registration statement and were underwritten by a syndicate of major financial institutions. This move suggests JNJ is actively managing its capital structure and potentially raising funds for general corporate purposes, such as financing operations, acquisitions, or repaying existing debt.

Johnson & Johnson (JNJ) announced the completion of a significant public offering of debt securities on February 20, 2025. The company successfully issued a total of $5.25 billion in notes across various maturities ranging from 2027 to 2035. This capital raise includes $750 million in 4.500% Notes due 2027, $750 million in 4.550% Notes due 2028, $1 billion in 4.700% Notes due 2030, $1.25 billion in 4.850% Notes due 2032, and $1.25 billion in 5.000% Notes due 2035. The offering was conducted under the company's existing shelf registration statement.

Johnson & Johnson's 2024 10-K filing reveals a company navigating a dynamic healthcare landscape, demonstrating resilience with an increase in total sales to $88.8 billion, a 4.3% rise from the previous year, driven by strong performance in the MedTech segment and growth in specific Innovative Medicine therapeutic areas like Oncology. The company continues to invest heavily in research and development, allocating $17.2 billion to drive innovation across its two core segments: Innovative Medicine and MedTech. Despite facing ongoing challenges such as patent expirations for key products like STELARA and REMICADE, increasing competition, and a complex regulatory environment, Johnson & Johnson is strategically positioning itself for future growth through acquisitions and pipeline advancements. The company also highlights its commitment to human capital management, focusing on attracting, developing, and retaining top talent, underscored by a competitive voluntary turnover rate of 6.3% in 2024.

Johnson & Johnson (JNJ) has filed an 8-K report on January 21, 2025, detailing its financial performance for the fourth quarter and full year ended December 29, 2024. The core of this filing is the press release (Exhibit 99.1) and supplementary financial data (Exhibit 99.2) which provide investors with key sales and earnings figures. While the filing itself does not contain granular operational details or forward-looking guidance, it serves as the official vehicle for disseminating the company's recently concluded fiscal period results.

Johnson & Johnson (JNJ) filed an 8-K/A amendment on January 22, 2025, primarily to furnish a press release dated January 22, 2025. This press release pertains to the period ended December 29, 2024, suggesting it contains updated financial or operational information relevant to the company's recent performance. Investors should review this press release for details on the company's performance and any potential implications for future outlook. While the filing itself is an amendment and does not introduce new material events, the attached press release is crucial for understanding JNJ's latest business developments and financial standing as of the fourth quarter of 2024. Investors are encouraged to examine the content of the press release for any announcements regarding sales, earnings, product pipelines, or strategic shifts that could impact the company's valuation and investment thesis.

Johnson & Johnson reported a total sales increase of 5.2% to $22.5 billion for the fiscal third quarter of 2024, with operational growth of 6.3%, partially offset by a negative currency impact. For the nine-month period, total sales grew by 4.0% to $66.3 billion, with operational growth of 5.6%. The company's Innovative Medicine segment showed resilient growth, with sales increasing by 4.9% in the third quarter and 3.9% for the nine-month period, driven by strong performance in Oncology and Pulmonary Hypertension, despite headwinds in Immunology and Infectious Diseases. The MedTech segment also demonstrated positive momentum, with sales up 5.8% for the quarter and 4.1% for the nine months, boosted by the acquisition of Shockwave Medical and strong performance in Electrophysiology and Cardiovascular areas. However, the company's earnings before provision for taxes saw a significant decrease in the third quarter to $3.3 billion from $5.2 billion in the prior year, primarily impacted by substantial charges related to talc matters ($2.0 billion in the quarter). The nine-month period showed an increase in earnings before taxes to $12.8 billion from $10.2 billion, driven by higher sales and a reduction in talc-related charges compared to the prior year's nine-month period. J&J continues to manage significant legal matters, particularly concerning talc and opioid litigation, which have led to substantial accruals and charges impacting profitability. The company's balance sheet remains robust, with cash and cash equivalents of $20.0 billion, and it continues to return capital to shareholders through dividends and share repurchases.

Johnson & Johnson (JNJ) filed an 8-K on October 15, 2024, to report its third-quarter 2024 financial results, which concluded on September 29, 2024. The filing primarily directs investors to the attached press release (Exhibit 99.1) for detailed sales and earnings information. While the 8-K itself does not contain the specific figures, it serves as the official notification and repository for the company's performance disclosure for the quarter.

Johnson & Johnson (JNJ) announced through its subsidiary Red River Talc LLC, the filing of a voluntary prepackaged Chapter 11 bankruptcy case on September 20, 2024. This strategic move is designed to comprehensively and permanently resolve all existing and future ovarian cancer claims stemming from cosmetic talc litigation in the United States. The filing was supported by a significant majority (approximately 83%) of current claimants for the proposed bankruptcy plan, indicating broad consensus among affected parties.

Johnson & Johnson (JNJ) filed an 8-K on September 10, 2024, primarily to announce the retirement of Director D. S. Davis. Mr. Davis stepped down from the Board of Directors after successfully transitioning his responsibilities as Chair of the Audit Committee to D. Adamczyk. The company emphasized that Mr. Davis's retirement is for personal reasons and is not indicative of any disagreements with the company's management or its operational, policy, or practice matters. This transition appears to be a planned succession within the Board's committee leadership.

Johnson & Johnson (JNJ) has announced a significant leadership transition via an 8-K filing on August 26, 2024. Peter M. Fasolo, the Executive Vice President and Chief Human Resources Officer (CHRO), has elected to retire. Mr. Fasolo will step down from his executive role and the Executive Committee effective October 1, 2024, and will officially depart the company by the end of the calendar year. This change marks the end of Mr. Fasolo's tenure in a key strategic position within the company's leadership structure. While the filing primarily reports on this executive departure, it is important for investors to note that a formal press release detailing this event has been issued and is included as an exhibit. Investors should monitor future filings for information regarding the appointment of a successor to Mr. Fasolo and any potential impact this leadership change may have on the company's human capital strategy, talent management, and overall organizational development.

Johnson & Johnson reported solid performance for the second quarter of 2024, demonstrating revenue growth driven by strong performance in its Innovative Medicine and MedTech segments. Total sales increased by 4.3% year-over-year to $22.4 billion, with operational growth of 6.6%, partially offset by currency headwinds. The Innovative Medicine segment saw a 5.5% increase in sales, propelled by robust growth in Oncology and Pulmonary Hypertension, despite a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for certain products. The MedTech segment also delivered growth, up 2.2%, boosted by acquisitions and strong performance in Cardiovascular and Orthopaedics. Financially, the company maintained healthy profitability, although earnings before taxes saw a slight decrease due to significant charges related to acquisitions and ongoing litigation settlements, particularly concerning talc matters. The company continues to navigate substantial legal proceedings, notably the talc and opioid litigations, which have resulted in significant accruals. Despite these challenges, Johnson & Johnson's liquidity remains strong, with substantial cash and cash equivalents, and effective management of its debt obligations. The company's strategic acquisitions, including Shockwave Medical, are expected to contribute to future growth, showcasing a continued focus on expanding its portfolio in key areas.

Johnson & Johnson (JNJ) filed an 8-K on July 17, 2024, primarily to disclose its financial results for the second quarter ended June 30, 2024. The filing includes a press release and supplementary sales data, offering investors a look into the company's operational performance and financial condition during the period. Investors should review the attached exhibits for detailed sales figures and earnings statements to understand the company's revenue generation and profitability trends.

Johnson & Johnson (JNJ) announced the completion of significant public offerings for both U.S. Dollar and Euro denominated notes on May 20, 2024. This filing details the issuance of approximately $4.0 billion in U.S. Dollar notes across various maturities (2029, 2031, 2034, and 2054) with coupon rates ranging from 4.800% to 5.250%. Additionally, JNJ issued approximately €2.5 billion in Euro notes with maturities in 2032, 2036, and 2044, carrying coupon rates from 3.200% to 3.550%. These offerings, conducted under the company's existing Form S-3 registration statement, represent a strategic move to raise capital. Investors should note that this transaction primarily relates to debt financing and does not involve equity issuance or significant operational updates. The filings also include details of the underwriting agreements with major financial institutions like J.P. Morgan, BofA Securities, and Citigroup.

Johnson & Johnson (JNJ) has finalized its divestiture of its remaining stake in its former Consumer Health business, now operating as Kenvue Inc. The company announced on May 17, 2024, that it completed a Debt-for-Equity Exchange. In this transaction, JNJ exchanged its remaining 182.3 million shares of Kenvue Common Stock for $3.6 billion aggregate principal amount of commercial paper that it had issued on May 15, 2024. This exchange effectively settles the commercial paper and marks the complete exit of Johnson & Johnson from its ownership of Kenvue. This strategic move concludes Johnson & Johnson's long-planned separation of its consumer health division. The initial separation began with Kenvue's IPO in May 2023, followed by a significant exchange offer in August 2023 that reduced JNJ's stake substantially. The final exchange of shares for debt removes any lingering ownership ties and allows Johnson & Johnson to fully focus on its pharmaceutical and medtech segments. Investors should view this as a significant step in JNJ's strategic realignment.

Johnson & Johnson (JNJ) filed an 8-K on May 1, 2024, primarily to disclose a significant development regarding its talc litigation. The company announced a proposed Plan of Reorganization to comprehensively resolve all current and future ovarian cancer claims in the United States, excluding certain specific claims. This resolution is contingent upon the payment of approximately $6.475 billion (present value) over 25 years, with a nominal value of roughly $8.4 billion. This proposed settlement has a material impact on JNJ's first-quarter 2024 financial results. The company recorded an incremental charge of approximately $2.7 billion, bringing the total reserve for these liabilities to a present value of approximately $11 billion. Consequently, reported GAAP net earnings for Q1 2024 have been reduced from $5.4 billion to $3.3 billion, and reported GAAP EPS has been lowered from $2.20 to $1.34. Importantly, these adjustments do not affect Adjusted Earnings, Adjusted EPS, or Adjusted Operational EPS, which remain unchanged.

Johnson & Johnson reported a strong first quarter for fiscal year 2024, with total sales reaching $21.4 billion, a 2.3% increase year-over-year, driven by robust operational growth of 3.9%. The company returned to profitability with net earnings of $3.3 billion, a significant improvement from a net loss of $68 million in the prior year's first quarter. This rebound was largely influenced by a substantial reduction in legal charges, particularly related to talc matters, which decreased from $6.9 billion to $2.7 billion year-over-year. The Innovative Medicine segment showed resilience with a 1.1% sales increase, supported by strong performance in Oncology and Pulmonary Hypertension, while the MedTech segment saw a 4.5% sales boost, led by growth in Cardiovascular and Orthopaedics. Despite some headwinds, including a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for key products, Johnson & Johnson demonstrated effective operational management and strategic execution. The company also continued its commitment to shareholder returns by declaring a quarterly dividend and actively repurchasing shares. The pending acquisition of Shockwave Medical, a significant move within the MedTech segment, signals a continued focus on strategic growth and portfolio enhancement.

Johnson & Johnson (JNJ) filed an 8-K on April 29, 2024, detailing key governance and shareholder meeting outcomes from their 2024 Annual Meeting held on April 25, 2024. The most significant corporate action was the adoption of amended and restated by-laws, which introduce updated procedures for shareholder actions, including calling special meetings and submitting director nominations or proposals. These changes aim to align with current regulatory standards, such as universal proxy rules, and clarify existing corporate governance practices. Furthermore, the filing provides the final voting results from the Annual Meeting. Shareholders overwhelmingly elected all 13 director nominees, approved executive compensation on an advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024. Notably, a shareholder proposal requesting a report on gender-based compensation gaps and associated risks was not approved.

Johnson & Johnson (JNJ) filed an 8-K/A amendment on April 16, 2024, primarily to provide an updated exhibit. This filing includes a press release dated April 16, 2024, which likely contains financial results for the period ended March 31, 2024. Investors should refer to this press release for the latest updates on the company's performance, including key financial metrics, segment results, and any forward-looking guidance that may have been provided. The nature of this filing as an amendment suggests that the original 8-K filing may have been incomplete or that additional information, specifically the press release, was required. Investors should carefully review the press release for details regarding JNJ's first-quarter 2024 performance, as this is the primary informational content being added via this amendment.

Johnson & Johnson (JNJ) filed an 8-K on April 16, 2024, to announce its first-quarter 2024 financial results and a significant increase in its quarterly dividend. The company reported its sales and earnings for the quarter ended March 31, 2024, as detailed in an attached press release (Exhibit 99.1). While specific financial figures are not detailed within the 8-K text itself, investors can access the comprehensive earnings report via the referenced exhibit for in-depth analysis of performance across its segments. Furthermore, the filing highlights a notable increase in shareholder returns. The Board of Directors approved a 4.2% hike in the quarterly dividend, raising it from $1.19 to $1.24 per share. This marks the 62nd consecutive year of dividend increases, underscoring JNJ's commitment to returning capital to shareholders and its consistent financial strength. The new annual dividend rate will be $4.96 per share.

Johnson & Johnson (JNJ) has filed its 10-K for the fiscal year ending December 30, 2023. The report highlights a strategic reorganization into two primary business segments: Innovative Medicine and MedTech, following the separation of its Consumer Health business (Kenvue). Financially, the company demonstrated robust sales growth, driven by strong performance in both segments, particularly in Oncology and MedTech's Interventional Solutions (boosted by the Abiomed acquisition). However, the company also reported a significant charge related to talc litigation, impacting overall earnings before taxes. Despite this, J&J maintained a strong liquidity position and continued its commitment to shareholder returns through dividends and share repurchases. Key risks highlighted include ongoing litigation, patent expirations, pricing pressures in the healthcare industry, and global economic uncertainties.

Johnson & Johnson (JNJ) filed an 8-K on January 23, 2024, to announce its fourth quarter and full-year 2023 financial results. The filing primarily directs investors to a press release (Exhibit 99.1) and supplementary financial data (Exhibit 99.2) containing detailed sales and earnings information for the periods ending December 31, 2023. Investors should review these attached documents for a comprehensive understanding of the company's performance, including revenue generation and profitability across its various segments.

Johnson & Johnson (JNJ) announced on December 5, 2023, that it will host an Enterprise Business Review meeting with the investment community. This event is designed to provide a comprehensive overview of the company's strategic direction, showcase its robust pipelines within both its Innovative Medicine and MedTech segments, and outline its long-term financial projections. Investors should pay close attention to the strategic updates and pipeline progress as these will be key drivers of future growth and profitability. The company has attached a press release regarding this Enterprise Business Review as an exhibit to its 8-K filing. Additional materials and webcast registration information are also made available, signaling the company's intent to ensure broad investor access to this significant strategic update. The focus on both segments suggests a balanced approach to growth, and the long-term financial outlook will be critical for assessing the company's future value proposition.

Johnson & Johnson announced a significant addition to its Board of Directors with the election of Eugene A. Woods, MBA, MHA, effective November 30, 2023. Mr. Woods brings valuable experience as the Chief Executive Officer of Advocate Health, a major healthcare system. This appointment is noteworthy as Advocate Health is a customer of Johnson & Johnson, purchasing medical technologies and pharmaceuticals in the ordinary course of business. While this creates a related-party transaction, the company has disclosed the approximate financial scale of these dealings, with Advocate Health spending around $175 million on JNJ products in fiscal year 2022 and JNJ spending less than $1 million on clinical trials with Advocate Health. Investors should view this appointment as potentially strengthening the Board's understanding of hospital operations and customer perspectives. The disclosure of the customer relationship is standard practice and provides transparency. Mr. Woods will receive standard non-employee director compensation as outlined in the company's proxy statement. The filing also includes the press release announcing this appointment as an exhibit.

Johnson & Johnson (JNJ) announced on November 30, 2023, the acquisition of Laminar, Inc. This strategic move, categorized as an asset acquisition, will result in an in-process research and development charge. Consequently, JNJ is revising its Adjusted Earnings Per Share (EPS) guidance for the fiscal year 2023. The company now anticipates Adjusted EPS to be between $9.85 to $9.91 on an operational basis and $9.90 to $9.96 on a reported basis. This reflects a reduction of approximately $0.17 from previously issued guidance due to the acquisition-related charge. Furthermore, the acquisition is projected to have a negative EPS impact of approximately $0.15 in fiscal year 2024.

Johnson & Johnson (JNJ) announced the adoption of a new Deferred Compensation Plan (the "Plan") effective November 21, 2023. This unfunded, nonqualified plan allows eligible management and highly compensated employees, including named executive officers, to defer a portion of their pre-tax base salary and annual cash performance bonuses. Participants can defer up to 50% of their base salary and 100% of their annual cash bonus for the following year. All amounts deferred, along with any investment gains or losses, are immediately vested with the employee. This plan replaces the previous Executive Income Deferral Plan (EIDP) for future deferrals, while existing EIDP balances will transition to the new plan's terms regarding payment timing and investment options.

Johnson & Johnson (JNJ) reported a mixed financial performance for the fiscal third quarter and nine months ended September 30, 2023. Total sales increased by 6.8% to $21.35 billion for the quarter and 6.2% to $63.76 billion for the nine months, driven by strong operational growth in both the Innovative Medicine and MedTech segments, as well as favorable currency impacts in the quarter. Despite the top-line growth, the company faced significant headwinds, including a substantial charge related to the talc settlement proposal which significantly impacted year-to-date earnings. The company also completed the significant separation of its Consumer Health business (Kenvue), which resulted in a large one-time gain from discontinued operations. The Innovative Medicine segment showed resilience with sales up 5.1% for the quarter and 4.2% year-to-date, with notable growth in immunology, oncology, and neuroscience products. The MedTech segment also demonstrated robust growth, up 10.0% for the quarter and 10.0% year-to-date, significantly boosted by the acquisition of Abiomed and strong performance in interventional solutions. However, the company's net earnings were heavily influenced by the large gain from discontinued operations related to the Kenvue separation, making direct comparison of profitability challenging without considering this non-recurring item.

Johnson & Johnson (JNJ) announced a significant leadership change within its MedTech segment via an 8-K filing dated October 23, 2023. Ashley McEvoy, Executive Vice President and Worldwide Chair of MedTech, has resigned from her position, effective October 20, 2023. She will remain with the company until the first quarter of 2024 to facilitate a transition period. This departure marks the end of her tenure on the Executive Committee and represents a notable change in leadership for a key segment of the company's operations.

Johnson & Johnson (JNJ) filed an 8-K on October 17, 2023, to announce its third-quarter financial results for the period ended October 1, 2023. The filing primarily references a press release (Exhibit 99.1) and supplementary financial data (Exhibit 99.2) detailing sales and earnings for the quarter and the year-to-date period. Investors should review the referenced exhibits for specific performance metrics, including revenue growth across segments and profitability. This report serves as the official notification of the company's latest financial performance, setting the stage for investor analysis and potential market reactions.

Johnson & Johnson (JNJ) has filed an 8-K report detailing the financial implications and updated guidance following the completion of its Kenvue Inc. separation. The company has finalized an exchange offer, effectively divesting its stake in Kenvue. This strategic move is expected to reshape JNJ's financial profile, allowing it to focus more intently on its core pharmaceutical and medical technology businesses. The press release accompanying this filing provides crucial updated financial figures and revised 2023 guidance. Investors should pay close attention to these adjustments, as they reflect the impact of the Kenvue Separation on JNJ's revenue streams, profitability, and overall financial outlook. The updated data will be essential for assessing the company's performance and future prospects as a more streamlined entity.

Johnson & Johnson (JNJ) has completed a significant strategic maneuver by finalizing its split-off exchange offer for Kenvue Inc. common stock. This transaction involved shareholders tendering their JNJ shares in exchange for Kenvue shares, effectively reducing Johnson & Johnson's ownership stake in the consumer health company. This move is a key step in JNJ's previously announced strategy to fully separate from Kenvue, allowing Johnson & Johnson to sharpen its focus on its two core segments: MedTech and Pharmaceuticals. Investors should note that this reduction in Kenvue shares represents a divestiture of a former subsidiary, which could impact future revenue and earnings profiles as JNJ streamlines its business operations.

Johnson & Johnson reported strong financial results for the second quarter of 2023, with worldwide sales increasing by 6.3% to $25.5 billion. This growth was driven by robust operational performance across all segments, particularly in MedTech and Pharmaceutical, which saw increases of 14.7% and 3.8% operationally, respectively. The company's net earnings rose to $5.14 billion, or $1.96 per diluted share, up from $4.81 billion, or $1.80 per diluted share, in the prior year's quarter. This performance demonstrates J&J's continued ability to navigate a complex global economic environment, supported by strategic pricing, innovation, and effective cost management. The company also made significant progress in its strategic separation of the Consumer Health business, Kenvue, through its successful IPO, positioning J&J to focus on its core healthcare businesses. The six-month period also showed positive momentum, with sales growing 6.0% to $50.3 billion and net earnings of $5.08 billion. While the six-month earnings were impacted by a significant charge related to the talc settlement proposal, the underlying operational performance remains strong. The company's diversified business segments, strong product pipeline, and strategic initiatives like the Kenvue separation are key drivers for future growth and shareholder value.

Johnson & Johnson (JNJ) has filed an 8-K report on July 28, 2023, to disclose a potential temporary trading suspension, commonly known as a "blackout period," for its directors and executive officers. This is in connection with the company's ongoing offer to exchange a significant portion of its Kenvue Inc. common stock for outstanding Johnson & Johnson shares. The blackout period is triggered if 50% or more of the participants in JNJ's employee benefit plans elect to tender their JNJ shares held within the company's stock fund as part of the Kenvue exchange offer. This is a regulatory requirement under Sarbanes-Oxley Act and Regulation BTR, aimed at restricting insider trading during certain corporate events that could affect employee benefit plans. If imposed, the blackout period is expected to commence around August 15, 2023, and last through the week of August 28, 2023, assuming the Kenvue exchange offer does not extend. During this time, JNJ's directors and officers will be restricted from buying or selling JNJ securities, with limited exemptions, though they will still have the opportunity to participate in the Kenvue exchange offer. Investors should note that this event primarily impacts insider trading and employee benefit plan participants, rather than the company's ongoing business operations or financial performance, but it signals a significant step in the Kenvue divestiture process.

Johnson & Johnson (JNJ) filed an 8-K on July 24, 2023, primarily to announce certain preliminary results for the period ended July 2, 2023. While the filing itself does not contain detailed financial statements, it incorporates by reference Exhibit 99.1, which presumably holds these preliminary results. Investors should refer to Exhibit 99.1 for specific figures related to the company's performance in the period. This type of filing typically precedes a more comprehensive earnings release and aims to provide timely updates on key performance indicators or significant developments.

Johnson & Johnson (JNJ) filed an 8-K on July 20, 2023, primarily to announce its second-quarter 2023 financial results. The report includes details on sales and earnings for the quarter ended July 2, 2023, as presented in an attached press release (Exhibit 99.1). This filing is crucial for investors seeking to understand the company's recent performance and financial health. While the 8-K itself is brief and acts as a vehicle for the press release, the information contained within that release is critical. Investors should pay close attention to the reported sales figures, earnings per share, and any commentary on the performance of JNJ's key business segments, including Pharmaceuticals and MedTech. The supplementary sales data and condensed consolidated statement of earnings provide a more detailed financial picture for the quarter and year-to-date period.

Johnson & Johnson (JNJ) has reported the completion of Kenvue Inc.'s initial public offering (IPO) on May 8, 2023. Kenvue, previously a wholly-owned subsidiary, offered 198,734,444 shares at $22.00 per share, raising approximately $4,241 million in net proceeds. These proceeds will be paid to Johnson & Johnson as partial consideration for the consumer health business transferred to Kenvue. Following the IPO, Johnson & Johnson retains a significant stake, owning approximately 89.6% of Kenvue's outstanding common stock. As a result, Johnson & Johnson will continue to consolidate Kenvue's financial results. The company also entered into a comprehensive Separation Agreement with Kenvue, outlining key corporate actions, asset and liability allocation, and agreements related to Kenvue's relationship with Johnson & Johnson post-IPO, including potential future dispositions of Kenvue shares.

This 8-K filing from Johnson & Johnson reports on the outcomes of their 2023 Annual Meeting of Shareholders held on April 27, 2023. A key event detailed is the departure of Thibaut Mongon from his Executive Vice President role to fully assume his CEO position at Kenvue Inc., following Kenvue's initial public offering. This transition marks a significant step in the separation and independent operation of the consumer health business. Shareholders overwhelmingly supported the re-election of all 12 director nominees and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor. The company also received advisory approval for its executive compensation and the annual frequency of such advisory votes. However, two shareholder proposals, one requesting a Vaccine Pricing Report and another on the impact of extended patent exclusivities on product access, did not receive sufficient support for approval. This filing provides clarity on corporate governance matters and key leadership changes impacting the company's structure.

Johnson & Johnson (JNJ) reported a net loss of $68 million ($0.03 per share) for the first quarter of 2023, a significant shift from the $5.15 billion net earnings ($1.93 per share) in the prior year. This was primarily driven by a substantial charge of $6.9 billion related to the talc settlement proposal, which significantly impacted the "Other (income) expense, net" line item. Despite the net loss, the company's operational performance remained robust. Worldwide sales grew by 5.6% to $24.7 billion, with operational growth of 9.0% driven by strong performances across all segments: Consumer Health (7.4%), Pharmaceutical (4.2%), and MedTech (7.3%). The MedTech segment saw a notable boost from the acquisition of Abiomed. The company also maintained a strong liquidity position with $26.9 billion in cash, cash equivalents, and restricted cash.

Johnson & Johnson (JNJ) filed an 8-K on April 18, 2023, primarily to report its first-quarter 2023 financial results and announce a dividend increase. The company's performance for the quarter ended April 2, 2023, was detailed in a press release (Exhibit 99.1), which is a key piece of information for investors assessing the company's operational health and profitability. The filing also includes supplementary sales data and condensed consolidated statements of earnings for the quarter. In addition to financial results, JNJ announced a significant increase in its quarterly dividend. The Board of Directors approved a 5.3% hike in the quarterly dividend rate, raising it from $1.13 to $1.19 per share. This translates to an annualized dividend of $4.76 per share, up from $4.52. This dividend increase underscores the company's financial strength and its commitment to returning value to shareholders, a positive signal for income-focused investors.